 Antigens, Neoplasm
"Antigens, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
| Descriptor ID |
D000951
|
| MeSH Number(s) |
D23.050.285
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antigens, Neoplasm".
This graph shows the total number of publications written about "Antigens, Neoplasm" by people in this website by year, and whether "Antigens, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 7 | 3 | 10 | | 1991 | 6 | 8 | 14 | | 1992 | 12 | 15 | 27 | | 1993 | 3 | 6 | 9 | | 1994 | 3 | 2 | 5 | | 1995 | 5 | 3 | 8 | | 1996 | 10 | 8 | 18 | | 1997 | 11 | 5 | 16 | | 1998 | 10 | 7 | 17 | | 1999 | 7 | 12 | 19 | | 2000 | 11 | 9 | 20 | | 2001 | 11 | 22 | 33 | | 2002 | 16 | 11 | 27 | | 2003 | 12 | 18 | 30 | | 2004 | 20 | 18 | 38 | | 2005 | 20 | 20 | 40 | | 2006 | 27 | 17 | 44 | | 2007 | 17 | 17 | 34 | | 2008 | 25 | 5 | 30 | | 2009 | 13 | 10 | 23 | | 2010 | 14 | 22 | 36 | | 2011 | 17 | 15 | 32 | | 2012 | 22 | 16 | 38 | | 2013 | 19 | 13 | 32 | | 2014 | 18 | 12 | 30 | | 2015 | 18 | 14 | 32 | | 2016 | 13 | 10 | 23 | | 2017 | 15 | 17 | 32 | | 2018 | 14 | 11 | 25 | | 2019 | 11 | 8 | 19 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antigens, Neoplasm" by people in Profiles.
-
Le Du F, Fujii T, Kida K, Davis DW, Park M, Liu DD, Wu W, Chavez-MacGregor M, Barcenas CH, Valero V, Tripathy D, Reuben JM, Ueno NT. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy. PLoS One. 2020; 15(3):e0229903.
-
Joseph J, Nathenson MJ, Trinh VA, Malik K, Nowell E, Carter K, Weathers SP, Demetri GD, Araujo D, Conley AP. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. J Immunother Cancer. 2019 11 08; 7(1):296.
-
Caruso HG, Tanaka R, Liang J, Ling X, Sabbagh A, Henry VK, Collier TL, Heimberger AB. Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function. J Neurooncol. 2019 Dec; 145(3):429-439.
-
Gros A, Tran E, Parkhurst MR, Ilyas S, Pasetto A, Groh EM, Robbins PF, Yossef R, Garcia-Garijo A, Fajardo CA, Prickett TD, Jia L, Gartner JJ, Ray S, Ngo L, Wunderllich JR, Yang JC, Rosenberg SA. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. J Clin Invest. 2019 11 01; 129(11):4992-5004.
-
Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019 10 24; 7(1):276.
-
Xu-Monette ZY, Li J, Xia Y, Crossley B, Bremel RD, Miao Y, Xiao M, Snyder T, Manyam GC, Tan X, Zhang H, Visco C, Tzankov A, Dybkaer K, Bhagat G, Tam W, You H, Hsi ED, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Winter JN, Medeiros JT, Xu B, Li Y, Kirsch I, Young KH. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
-
Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, Dyson KA, Grippin AJ, Deleyrolle LP, Zhang W, Rajon DA, Wang QJ, Yang JC, Kresak JL, Sayour EJ, Rahman M, Bova FJ, Lin Z, Mitchell DA, Huang J. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019 09 05; 10(1):4016.
-
Kula T, Dezfulian MH, Wang CI, Abdelfattah NS, Hartman ZC, Wucherpfennig KW, Lyerly HK, Elledge SJ. T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. Cell. 2019 08 08; 178(4):1016-1028.e13.
-
Hont AB, Cruz CR, Ulrey R, O'Brien B, Stanojevic M, Datar A, Albihani S, Saunders D, Hanajiri R, Panchapakesan K, Darko S, Banerjee P, Fortiz MF, Hoq F, Lang H, Wang Y, Hanley PJ, Dome JS, Bollard CM, Meany HJ. Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. J Clin Oncol. 2019 09 10; 37(26):2349-2359.
-
Keung EZ, Wargo JA. The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surg Oncol Clin N Am. 2019 07; 28(3):369-386.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|